We are live on ! Find out more
ORKA icon

Oruka Therapeutics
ORKA

16 hedge funds and large institutions have $21.3M invested in Oruka Therapeutics in 2016 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

733% more capital inflows, than outflows

Capital inflows: $698K | Capital outflows: $83.8K

1.85% more ownership

Funds ownership: 66.24% → 68.09% (+1.9%)

0% more funds holding

Funds holding: 16 → 16 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
16
Holders Change
–
Holders Change %
0%
% of All Funds
0.42%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
2
Increased
3
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Royce & Associates
Royce & Associates
New York
+$677K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$9.8K
3
Virtu KCG Holdings
Virtu KCG Holdings
New York
+$4.88K
4
Walleye Trading
Walleye Trading
New York
+$4.07K
5
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
+$2.44K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$83K
2
Citigroup
Citigroup
New York
-$814

ORKA Hedge Fund Activity: Q1 2016 in Review

16 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q1 2016, worth a combined $21.3M — down 24% from $27.9M a quarter earlier.

Fund positioning in ORKA was balanced in Q1 2016: 2 funds opened new positions, 2 closed out, 3 added to existing stakes and 0 trimmed.

The largest buyer was Royce & Associates, opening a new position worth an estimated $677K. The largest seller was Citadel Advisors, exiting entirely with an estimated $83K sold.

  • 16 institutional investors held Oruka Therapeutics (ORKA) as of Q1 2016, unchanged from Q4 2015.
  • Funds reported $21.3M of Oruka Therapeutics stock for Q1 2016, down 24% quarter-over-quarter.
  • 2 funds opened new Oruka Therapeutics positions in Q1 2016 and 2 closed out, a net change of 0 holders.
  • The largest Oruka Therapeutics buyer in Q1 2016 was Royce & Associates, an estimated $677K added.
  • The largest Oruka Therapeutics seller in Q1 2016 was Citadel Advisors, an estimated $83K sold.

Based on aggregated 13F filings for Q1 2016.